Enasidenib for Acute Myeloid Leukemia

"Unfortunately, this clinical trial has suspended the recruitment of participants. It was first posted on July 17th 2018 and last updated on August 8th 2022. If you are seeking alternative medical studies related to cancer, there is a current pool of 3835 trials actively recruiting patients with cancer, as well as 24 Enasidenib-specific studies taking onboard new members."

"Enasidenib has been studied since 2013, when the drug was first sponsored by Celgene and scrutinized in a trial involving 345 participants. After being approved for Phase 1 & 2 trials, 24 distinct clinical studies are now taking place across 84 cities and 28 countries."

"The primary outcome of this 28-day trial is to determine the Maximum Tolerable Dose (MTD). The number and severity of Enasidenib-related adverse events will be monitored based on Common Terminology Criteria for Adverse Events (CTCAE 4) standards. Additionally, researchers are looking into cumulative incidence of chronic GVHD, which is graded from mild to severe using an aggregate score system featuring 0 for no symptoms and 3 as the most serious signs. Lastly, a summary of mutations in the Isocitrate dehydrogenase gene via next-generation sequencing will also be evaluated."

"Due to the fact that this is a first phase trial, with limited evidence in support of efficacy and safety, Enasidenib was given a score of 1."

"Unfortunately, the clinical trial listed on clinicaltrials.gov is not presently recruiting candidates; although it was last updated as recently as August 8th 2022. However, 3859 other studies are currently welcoming participants."

"Currently, 24 separate clinical trials focusing on Enasidenib are in progress. Of those studies, two have already reached Phase 3 testing. While Edmonton is a common site for these experimentations, there are over 600 other locations worldwide offering access to this medication trial."